Bharat Tewarie - UCB SA Insider

UCB SA -- USA Stock  

USD 41.40  0.000002  0.00%

Executive Vice President Chief Marketing Officer

Dr. Bharat Tewarie has served as Executive Vice President, Chief Marketing Officer, Member of the Executive Committee of UCB S.A. since March 2015. He joined the Company in March 2015. He received an MBA from Webster University in 1991, and a Masters degree from Universiteit Utrecht in 1986. He joined UCB with 27 years of experience in the biotech industry. He has acquired worldwide expertise while leading global business unit teams to great success. His past experience in domains such as immunology and neurology are a great match to UCBs core focus areas. His knowledge of markets around the world is also key to helping UCB prepare for future product launches. Trained as a medical doctor, he also has background in multiple aspects of pharmaceutical management, including PL responsibility, business development, sales, global marketing, clinical research and medical affairs. At UCB he heads the Global Strategic Marketing Practice and is a member of the Executive Committee. Key positions Prior to UCB 2012 2014 EMD Serono Inc. Senior Vice President, Head of the Global Business Franchise Neurology and Immunology and of the Global Business Franchise Medical Devices 2010 2011 Merck Serono SA Senior Vice President, Head of Global Business Unit Fertility Endocrinology 1998 2010 During this timeframe, Bharat held various leadership positions at Serono International SA, Serono Inc and EMD Serono in Endocrinology and Reproductive Health covering areas such as global sales and marketing, US business unit management and business development Prior to this, he built up his global and local experience with other companies Roche Pharma and Boehringer Ingelheim.
Age: 56  President Since 2015  MBA    
32 2 559 99 99

Management Efficiency

The company has return on total asset (ROA) of 6.67 % which means that it generated profit of $6.67 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of 13.73 % meaning that it generated $13.73 on every $100 dollars invested by stockholders.
The company has accumulated 1.93 B in total debt with debt to equity ratio (D/E) of 27.4 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. UCB SA has Current Ratio of 1.34 which is within standard range for the sector.

Similar Executives

Entity Summary

UCB SA, a biopharmaceutical company, focuses on the discovery and development of medicines and solutions for people living with severe diseases of the immune system or of the central nervous system. UCB SA was founded in 1928 and is based in Brussels, Belgium. UCB SA operates under Biotechnology classification in USA and traded on OTC Market. It employs 7478 people.UCB SA (UCBJY) is traded on OTC Market in USA. It is located in All?e de la Recherche, 60 and employs 7,478 people.

UCB SA Leadership Team

Pascale Richetta, President
Detlef Thielgen, CFO
Kay Davies, Director
Dirk Teuwen, VP
Anna Richo, EVP
Viviane Monges, Director
Gerhard Mayr, Chairman
Cyril Janssen, Director
Cedric Rijckevorsel, Director, CFA
JeanChristophe Tellier, Chairman
Arnoud Calesberg, Director
Mark McDade, COO
Xavier Michel, President
Dhavalkumar Patel, President
Bharat Tewarie, President, MBA
Roch Doliveux, Chairman
Norman Ornstein, Director
Jeff Wren, President
JeanPierre Kinet, Director, Ph.D
Antje Witte, VP
Alice Dautry, Director
Harriet Edelman, Director, MBA
Ulf Wiinberg, Director
Thomas McKillop, Director, Ph.D
Charl Zyl, President
France Nivelle, VP
Fabrice Enderlin, President
Pierre Gurdjian, Director
Ismail Kola, EVP, Ph.D
Emmanuel Caeymaex, President
Evelyn Bergendal, Executive
Iris LoewFriedrich, President, Ph.D
CharlesAntoine Janssen, Director
Albrecht Graeve, Director
JeanLuc Fleurial, President
Alexander Moscho, President

Stock Performance Indicators

Did you try this?

Run Analyst Recommendations Now

Analyst Recommendations

Analyst recommendations and target price estimates broken down by several categories
Hide  View All  NextLaunch Analyst Recommendations

Trending Equities

Currently Active Assets on Macroaxis
Purchased over 20 shares of
few hours ago ago
Traded for 137.54
Purchased over 200 shares of
few hours ago ago
Traded for 11.33
Purchased over 20 shares of
few hours ago ago
Traded for 124.48
Purchased over 70 shares of
few hours ago ago
Traded for 38.93
Purchased over 200 shares of
few hours ago ago
Traded for 11.33
Purchased over 100 shares of
few hours ago ago
Traded for 25.72
Also please take a look at World Market Map. Please also try Fund Screener module to find activelly-traded funds from around the world traded on over 30 global exchanges.